Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.

Spontaneous Bacterial Peritonitis Clinical Trial

Official title:

A Randomized Non-inferiority Trial Comparing Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04273373
• Other study ID #: ILBS-AKI-03
• Status: Completed
• Phase: N/A
• Start date: March 1, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2022
• Source: Institute of Liver and Biliary Sciences, India
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

AIM:- A randomized non-inferiority trial comparing low dose albumin versus standard dose albumin in high risk Spontaneous Bacterial Peritonitis. Methodology In this non-inferior randomized controlled trial one group will receive Low dose albumin: 20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours and other group will receive Standard dose albumin: 20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 h (duration of infusion 6 hours). Study population: Patients of age > 18 years of age with cirrhosis of liver who are admitted in ward/Intensive Care Unit diagnosed with Spontaneous Bacterial Peritonitis. Study design: Randomized controlled trial Study period: September 2019- September 2020 Sample size: 300 (150 cases in each group) If there is a true difference in favour of the experimental treatment of 5 % then 270 patients are required to be 80% sure that the upper limit of a one sided 95% confidence interval (or equivalently a 90 % two-sided confidence interval) will exclude a difference in favour of the standard group of more than 5 %. And if the investigators consider 10% drop out final sample size is 270+30=300. 150 in each limb. Cases will be randomly allocated in 2 groups by block randomization method with block size taken as 10. Monitoring and assessment: all the parameters of the objective and also noted any adverse effects. Adverse Effects: Nausea, Vomiting, Fever with chills, dyspnea Stopping Rule: in the event of any of the adverse effects during therapy. Expected Outcome of the project: Proportion of patients having new development or progression of Acute Kidney Injury by day 7

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. >18 years of age

2. Cirrhosis with SBP (community acquired, health care associated and nosocomial) and baseline serum bilirubin =4 mg/dl and/or SCr = 1 mg/dl.

Exclusion Criteria:

1. Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin)

2. Significant cardiac failure, pulmonary disease

3. Known CKD ( Chronic Kidney Disease)or findings suggestive of organic nephropathy (proteinuria, haematuria, or Abnormal findings on renal USG)

4. Hepatocellular carcinoma

5. HIV (Human Immunodeficiency Virus) infection;

6. GI (Gastrointestinal) bleed within 1 month before the study

7. Ileus

8. Grade 3 to 4 hepatic encephalopathy

9. Other types of infection

10. Shock

11. Presence of any potential causes of dehydration (such as diarrhoea or an intense response to diuretic treatment) within one week before the diagnosis of SBP).

12. Baseline serum bilirubin <4 mg/dl or S. Cr < 1 mg/dl

13. Serum creatinine level of > 3.0 mg/dl.

Related Conditions & MeSH terms

• Peritonitis
• Spontaneous Bacterial Peritonitis

Intervention

Biological:
• Low Dose Albumin
20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
• Standard dose Albumin
20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).

Locations

Country	Name	City	State
India	Institute of Liver and Biliary Sciences	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients having new development or progression of Acute Kidney Injury in both groups		Day 7
Secondary	Number of participants with resolution of Spontaneous Bacterial Peritonitis in both groups		Day 7
Secondary	Changes in RRI (Renal Resistive Index) in both groups		Day 6
Secondary	Number of participants who will develop volume overload in both groups		Day 7
Secondary	Number of participants who will not survive in both groups.		Day 7
Secondary	Number of participants who will not survive in both groups.		Day 28